We have characterized UNKC6141 mouse pancreatic ductal adenocarcinoma for analyzing the efficacy of therapies for pancreatic cancer. The genetic profile of UNKC6141 cells mimics the natural progression of PDAC in human mutagenesis.
This cell line has metastatic potential in the liver, spleen, small intestines, and lymph nodes.
This cell line displays aggressive growth in both orthotopic and syngeneic (flank) models.
UNKC6141 PDAC Mouse Model
UNKC6141 Pancreatic Ductal Carcinoma Model with high mutational burden.
UNKC6141 is a mouse pancreatic ductal adenocarcinoma cell line (PDAC) derived from pancreatic tumors of KrasG12D Pdx1-Cre (KC) mice and expresses the ductal marker CK19. UNKC6141 cell line grows aggressively after subcutaneous and orthotopic applications with consistent recovery in peripheral blood, bone marrow, lung and liver.
Models such as UNKC6141 play a huge role in understanding PDAC progression, metastasis and heterogeneity. With take rates of 100% in flank and orthotopic injections and a 30 day model duration, the UNKC6141 model can provide valuable information to pancreatic cancer immunotherapies.
Resectable or borderline resectable treatment options include (Neoadjuvant therapy, surgery, postoperative chemotherapy or chemoradiation). Locally advanced treatment options to include chemotherapy with/without targeted therapy, chemoradiation, surgery or palliative surgery. Metastatic or recurrent treatment options typically involve chemotherapy with/without targeted therapy.